Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGX942 for oral mucositis in head and neck cancer
NCT02013050Phase 2Completed
- Sponsor
- Soligenix
- Start
- Dec 2013
- Primary completion
- Dec 2015
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dusquetide in oral mucositis (OM) (4 arms), sponsored by Soligenix. Primary endpoint: Duration of Severe Oral Mucositis. Started Dec 2013; status: completed.
02
Drugs
dusquetide
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT02013050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013050.